Literature DB >> 8892486

Assessing the minimal important difference in symptoms: a comparison of two techniques.

D A Redelmeier1, G H Guyatt, R S Goldstein.   

Abstract

We have developed a method for estimating the minimally important difference (MID) for health status measures. Whereas the conventional approach requires patients to judge themselves relative to their memories, our method requires patients to judge themselves relative to others with the same condition. In this study we examined whether our method (based on between-patient differences) and the conventional method (based on within-patient changes) provides comparable estimates of the MID for one health status measure: the Chronic Respiratory Questionnaire. Patients with chronic obstructive pulmonary disease who were participating in a supervised respiratory rehabilitation program were included if they were in stable health (n = 112). Their mean score per question in the Chronic Respiratory Questionnaire was 4.5 (range, 1 to 7; where bigger values indicate better health). Our method estimated that the MID was 0.5 (95% confidence interval 0.4 to 0.7). This estimate was similar to the MID previously found using the conventional method. These observations support the role of the Chronic Respiratory Questionnaire for measuring patient's symptoms, the validity of our approach for assessing the MID, and an estimate on the order of 0.5 as the threshold for this particular health status measure.

Entities:  

Mesh:

Year:  1996        PMID: 8892486     DOI: 10.1016/s0895-4356(96)00206-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  86 in total

1.  Bayesian communication: a clinically significant paradigm for electronic publication.

Authors:  H P Lehmann; S N Goodman
Journal:  J Am Med Inform Assoc       Date:  2000 May-Jun       Impact factor: 4.497

2.  Measuring Quality of Live in Disorders of Sleep and Breathing.

Authors:  Marlene Reimer; W. Ward Flemons
Journal:  Sleep Breath       Date:  1999       Impact factor: 2.816

3.  Reassessing quality-of-life instruments in the evaluation of new drugs.

Authors:  G H Guyatt; R J Jaeschke
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

Review 4.  Pulmonary rehabilitation.

Authors: 
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 5.  Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

Authors:  Anke Lenferink; Marjolein Brusse-Keizer; Paul Dlpm van der Valk; Peter A Frith; Marlies Zwerink; Evelyn M Monninkhof; Job van der Palen; Tanja W Effing
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

Review 6.  Determination of the clinical importance of study results.

Authors:  Malcolm Man-Son-Hing; Andreas Laupacis; Keith O'Rourke; Frank J Molnar; Jeffery Mahon; Karen B Y Chan; George Wells
Journal:  J Gen Intern Med       Date:  2002-06       Impact factor: 5.128

7.  Health status measurement: sensitivity of the self-reported Chronic Respiratory Questionnaire (CRQ-SR) in pulmonary rehabilitation.

Authors:  J E A Williams; S J Singh; L Sewell; M D L Morgan
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

8.  Outcomes in Cardiopulmonary Physical Therapy: Chronic Respiratory Disease Questionnaire (CRQ).

Authors:  Alyssa Chauvin; Laurel Rupley; Katie Meyers; Kristin Johnson; Jane Eason
Journal:  Cardiopulm Phys Ther J       Date:  2008-06

Review 9.  Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report.

Authors:  Kathleen W Wyrwich; Stephan D Fihn; William M Tierney; Kurt Kroenke; Ajit N Babu; Fredric D Wolinsky
Journal:  J Gen Intern Med       Date:  2003-03       Impact factor: 5.128

10.  Clinically important change in quality of life in epilepsy.

Authors:  S Wiebe; S Matijevic; M Eliasziw; P A Derry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.